Pimicotinib

Phase 2Small molecule

AAbbisko Therapeutics Co, Ltd

Pimicotinib is one of 42 small molecule programs targeting Tenosynovial Giant Cell Tumor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Tenosynovial Giant Cell TumorRecruiting

Tenosynovial Giant Cell Tumor, DiffuseNot yet recruiting

Pancreatic CancerRecruiting

Tenosynovial Giant Cell TumorPhase 2

Recruiting

Tenosynovial Giant Cell Tumor, DiffusePhase 2

Not yet recruiting

Pancreatic CancerPhase 2

Recruiting

Competition

Competitive Landscape

335 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Byetta

AstraZeneca

Preclinical

1 2

Pimicotinib

AAbbisko Therapeutics Co, Ltd

Phase 2

1 3

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 4

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 7

Active Comparator

Moderna

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

Hyperpolarized 13c Pyruvate

UUniversity of Maryland, Baltimore

Preclinical

1 10

PEG-Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Pancreatic Cancer

NCT06111274

Q4 2029

Phase 2Recruiting

Tenosynovial Giant Cell Tumor

NCT07499362

Q3 2030

Phase 2Not yet recruiting

Tenosynovial Giant Cell Tumor, Diffuse

NCT07707882

Clinical

Trials by Indication[1]

Moderate Hepatic Impairment1 trial

The Study to Assess the Pharmacokinetics of Pimicotinib in Subjects With Mild and Moderate Hepatic Impairment Relative to Subjects With Normal Hepatic Function

Completed·AAbbisko Therapeutics Co, Ltd·Phase 1·NCT06562946·24 enrolled

Pancreatic Cancer1 trial

A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer

Recruiting·AAbbisko Therapeutics Co, Ltd·Phase 2·NCT06111274·82 enrolled

AIN1 trial

A Study to Evaluate the Relative Bioavailability of Pimicotinib Capsules Containing Free Base in Different Proportions in Healthy Subjects

Completed·AAbbisko Therapeutics Co, Ltd·Phase 1·NCT07210996·20 enrolled

Metformin1 trial

A Study to Investigate The Effect of Pimicotinib on The Pharmacokinetics of Metformin, Fexofenadine and Rosuvastatin In Healthy Subjects

Completed·AAbbisko Therapeutics Co, Ltd·Phase 1·NCT06779253·39 enrolled

Tenosynovial Giant Cell Tumor1 trial

Phase 2, Single-arm Study to Investigate the Tolerability, Pharmacokinetics, Efficacy, and Safety of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT07499362·20 enrolled

2 more indications

Tenosynovial Giant Cell Tumor, Diffuse1 trial

Neoadjuvant Pimicotinib Combined With Surgery Versus Upfront Surgery for Diffuse Tenosynovial Giant Cell Tumor: A Randomized, Open-label Trial

Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT07707882·84 enrolled

Unspecified3 trials

A Study to Evaluate the Effect of a High-fat Meal on the Exposure of Pimicotinib Capsule in Healthy Subjects

Active, not recruiting·AAbbisko Therapeutics Co, Ltd·Phase 1·NCT06884072·16 enrolled

A Study to Evaluate the Relative Bioavailability of Two Different Pimicotinib Capsules in Healthy Subjects

Completed·AAbbisko Therapeutics Co, Ltd·Phase 1·NCT06694948·26 enrolled

A Study to Evaluate the the Bioequivalence of Two Different Pimicotinib Capsules in Healthy Subjects

Completed·AAbbisko Therapeutics Co, Ltd·Phase 1·NCT07126249·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Pimicotinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pimicotinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pimicotinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Abbisko Therapeutics Co, Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAbbisko Therapeutics Co, Ltd

Pimicotinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2029

Q3 2030

Trials by Indication[1]

Moderate Hepatic Impairment1 trial

Pancreatic Cancer1 trial

AIN1 trial

Metformin1 trial

Tenosynovial Giant Cell Tumor1 trial

Tenosynovial Giant Cell Tumor, Diffuse1 trial

Unspecified3 trials

References

Drug Info

Quick Facts

Related News